Last updated: February 24, 2026
What is NDC 00574-0790 and its approved indications?
NDC 00574-0790 corresponds to Vasopressin Injection (Supplied by multiple manufacturers, primarily Ferring Pharmaceuticals). It is approved for use in septic shock, vasodilatory shock, cardiac arrest, and as a vasopressor or for diabetes insipidus.
Market size and demand drivers
Current utilization
Vasopressin remains a critical agent in shock management, especially in septic shock. The U.S. market for vasopressors was valued at approximately $600 million in 2022 and expected to grow at a compound annual growth rate (CAGR) of around 4-6% through 2027 [1].
Key demand factors
- Increasing prevalence of septic shock, projected to affect 1.7 million Americans annually [2].
- Expansion of ICU capacity and use of vasopressors in critical care settings.
- Shortages and supply chain issues with leading brands, prompting formulary switches.
Competitive landscape
- Other vasopressors include norepinephrine, epinephrine, and phenylephrine.
- Biosimilar and generic versions of vasopressin are gaining market share, reducing prices.
- Ferring's product faces competition from other manufacturers offering similar formulations.
Price analysis
Historical and current pricing
- Brand-name vasopressin (e.g., Ferring) costs approximately $45-$60 per 20 mL vial (concentration 20 units/mL).
- Generic versions are priced around $15-$30 per vial.
- Bulk hospital contracts and Medicare pricing can lower per-unit costs further.
Price trends and forecasts
| Year |
Average Price per Vial |
Notes |
| 2022 |
$50 |
Current market average for brand-name products |
| 2023 |
$45-$55 |
Slight decline due to increased biosimilar competition |
| 2024 |
$40-$50 |
Expected further decrease as biosimilars expand market share |
| 2025 |
$35-$45 |
Potential stabilization with limited differentiation |
Market-driven pricing projections
- The price of NDC 00574-0790 is likely to decline at a CAGR of 3-4% over the next three years, driven by biosimilar entry.
- Hospitals and payers will prefer lower-cost biosimilars, applying downward pressure on list prices.
- Volatility may occur during shortages, leading to temporary price increases.
Regulatory and policy impact
- The FDA has approved multiple biosimilars for vasopressin, targeting increased competition.
- Centers for Medicare & Medicaid Services (CMS) policies favor biosimilar substitution, influencing overall pricing.
- Future price regulation could emerge, especially if federal policies aim to curb drug costs.
Key factors influencing future market and pricing
- Continued development and approval of biosimilars.
- Clinician and hospital adoption rates of biosimilars versus branded products.
- Supply chain stability affecting availability and pricing.
- Changes in ICU usage patterns and septic shock management protocols.
- Potential shifts in reimbursement policies and formularies.
Summary: Market outlook
The vasopressin segment, including NDC 00574-0790, faces a steady decline in prices driven by biosimilar competition and policy shifts. Market size remains significant due to critical care needs, but the profit margin on branded products diminishes. Cost containment strategies will prioritize biosimilars, leading to more aggressive pricing.
Key takeaways
- The current U.S. market size is approximately $600 million, growing modestly.
- Prices are expected to decline 3-4% annually over the next three years.
- Competition from biosimilars is a primary driver for price reductions.
- Supply chain disruptions can cause short-term price spikes.
- Payers and hospitals will prioritize biosimilar adoption to reduce costs.
FAQs
Q1: When are biosimilars for vasopressin expected to dominate the market?
A1: Biosimilars are already in the market and are projected to capture increasing market share through 2025-2027.
Q2: How do regulatory policies impact vasopressin pricing?
A2: FDA approval of biosimilars facilitates competition, pressuring prices downward. Reimbursement policies favor biosimilar substitution, further influencing pricing trends.
Q3: What factors could reverse the declining price trend?
A3: Supply shortages, regulatory delays for biosimilars, or changes in septic shock treatment guidelines could temporarily stabilize or increase prices.
Q4: How does hospital procurement influence vasopressin prices?
A4: Hospitals negotiate bulk contracts, often securing lower prices, which can undercut retail prices and influence market averages.
Q5: What role do innovations in shock management play in market dynamics?
A5: Advancements reducing vasopressin's role or introducing alternative therapies could decrease demand and suppress prices.
References
[1] IQVIA. (2023). U.S. Hospital & Outpatient Market Data.
[2] CDC. (2022). Sepsis and Septic Shock Statistics.
[3] GoodRx. (2023). Vasopressin Price Trends.
[4] FDA. (2022). Biosimilar Approvals and Guidance.
Note: Price forecasts are subject to change based on market dynamics, policy shifts, and development of new therapies.
